Praxis Precision Medicines, Inc. (PRAX)

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen

Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report)'s share price reached a new 52-week high on Friday. The stock traded as high as $249.97 and last traded at $255.4490, with a volume of 59852 shares changing hands. The stock had previously closed at $189.97. Analyst Ratings Changes A number of research analysts have

Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10- what's going on?

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), following a recommendation by the Data Monitoring Committee to stop the study early for efficacy. “SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they impose on patients, and there are currently no approved treatment options.

Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026 Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on December 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,594 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Geode Capital Management LLC lifted its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 8.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 451,731 shares of the company's stock after purchasing an additional 33,715 shares during

Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a large unmet market. Upcoming PRAX catalysts include a pre-NDA meeting with the FDA in Q4 2025 and a potential NDA filing for Ulixacaltamide in 2026, alongside advancing late-stage trials for Vormatrigine and Relutrigine.

Praxis Precision Medicines, Inc. ( PRAX ) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies November 24, 2025 1:00 PM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Chuck McCullogh Presentation Douglas Tsao H.C.

Praxis Precision Medicines, Inc. ( PRAX ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division All right. We're going to get started with our next session.

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis' Ulixacaltamide Data with statistician Prof. Chuck McCullogh, University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza, Praxis' CEO.

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ: PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.

Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses.